# Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)

> **NCT01078220** · — · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 189629 (actual)

## Conditions studied

- Human Papillomavirus Infection

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01078220
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-06
- **Primary completion:** 2010-12-13
- **Final completion:** 2010-12-13
- **Target enrollment:** 189629 (ACTUAL)
- **Last updated:** 2017-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01078220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01078220, "Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01078220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*